In the random-effects model ( Figure 2 ), the keverprazan-based treatment showed a trend toward higher eradication rates than the esomeprazole-based treatment (treatment effect (TE) = 0.06; 95% CI: −0.01–0.13; P = .0759), although the difference was not statistically significant.
Somewhat surprisingly, at 9 months, the Q175 Het and Hom mutants showed a trend towards better performance on the test than the WT controls ( F 2,22 = 2.935, P = 0.076), but this paradoxical finding was reversed by 12 months, where there was a gene dose-dependent decline in motor function ( Fig. 6A ; F 2,22 = 11.557, P <0.001) with post hoc comparisons revealing that Het mice performed worse than WT ( t = 2.419, P = 0.025) and Hom mice performed worse than both age-matched Het and WT mice ( vs Het t = 2.225, P = 0.0378; vs WT t = 4.806, P = 0.017).
Additionally, post hoc analyses revealed the following relationships between mass and wound size within family on either Day 6 or Day 10 of wound-healing; Family B showed a trend toward a positive relationship between mass and wound size on Day 10 during both X 1 ( F 1,7 = 5.68, P = 0.076, estimate = 0.27) and X 2 ( F 1,7 = 4.72, P = 0.066); all other relationships were non-significant (all F 1,7 < 1.54, all P > 0.25, -0.16 < all estimates < 0.12).
Surgical time exceeding 4 h showed a trend toward higher risk (OR = 1.87, 95% CI: 0.94–3.75, P = 0.076), while anesthesia time greater than 4 h was significantly associated with elevated risk (OR = 2.97, 95% CI: 1.44–6.12, P = 0.003).
When compared with BC alone, this dual modality for tissue examination showed a trend toward increasing sensitivity from 36.1% to 50.7% ( p = 0.076).
Comparison of patients without signs of myocardial fibrosis in MRI (LGE negative; n = 12) to patients with signs of fibrosis (LGE positive; n = 18) revealed similar myocardial lipid content in both groups ( p > 0.05), while the latter showed a trend towards elevated LV mass ( p = 0.076).
However, the NP-B6 conjugate-treated P301S slice culture samples showed a trend towards increased levels of hTAU as compared to the slice cultures receiving other NP treatments ( Figure 5 f, p = 0.076), implicating that some pTAU might have been caught with B6 and pulled into the magnetic fraction by conjugated iron-cored NP using magnetic separation.
The time spent in the center of the arena ( Figure 3E ) showed a trend for an increase over time [ F (2,259) = 2.609, p = 0.076].
However, after adjusting for age, initial NIHSS correlated positively with the FLT‐binding ratio ( r = 0.61, p = 0.035) and early NIHSS decline showed a trend toward positive correlation with the FLT‐binding ratio ( p = 0.076); after additional adjustment for infarct volume, the significance was lost, but there was still a trend toward positive correlation between early NIHSS decline and FLT‐binding ratio ( p = 0.147).
The hours spent variable showed a trend in explaining EE ( p = 0.076), and age was significant ( p = 0.008) (see Table 7 ).
Notably, within this subgroup, patients receiving ≥ 2 cycles of neoadjuvant immunochemotherapy showed a trend towards better overall survival ( P = 0.076) and disease-free survival ( P = 0.062).
Participants’ responses showed a trend of being slower when switching entailed greater costs ( t 28 = 1.844, p = 0.076, CI 95 = [−0.003 to 0.056], U3 1 = 0.345).
Postprandial BDNF concentrations in serum decreased significantly after the high-fat ( P = 0.013) and high-carbohydrate meals ( P = 0.040), and showed a trend after the high-protein meal ( P = 0.076).
Although NLR did not reach statistical significance in this cohort, week 1 NLR showed a trend toward prognostic relevance (HR = 2.034, p = 0.076) ( Figure 4 ).
PPP1R1B (also known as DARPP-32) levels were significantly altered across disease stages ( Supplementary Table 2 , P = 0.042) and showed a trend towards decreased levels in late HD compared with early/mid HD groups (MD = 0.3682, 95% CI: −0.029–0.765, P = 0.076).
The duration of illness only showed a trend of correlation with baseline PANSS total scores ( R 2 = 0.02, p = 0.076).
In contrast, adding suPAR improved GNRI performance (AUC 0.723, p=0.077) and showed a trend toward improved PNI (AUC 0.694, p=0.076), although neither reached statistical significance.
Although the E4/DRSP group showed a trend toward a shorter duration from pill initiation to ovulation than the EE/GS group (4.71 ± 1.60 days vs. 6.86 ± 2.27 days), the difference was not significant ( p = 0.076).
The following trends were observed: mnemonics were better received when not combined with studies ( p =0.132), and combining a study with a comic showed a trend toward increased interest ( p =0.076).
Whilst FLICA16 showed a trend for the indirect path ( path ab : p-value = 0.076), the Total and the Direct effects were both statistically significant (p-value = 0.008 and 0.030, respectively) (more details see Tables S2 ).
Patients with cardiac resynchronization therapy (CRT‐D) showed a trend toward more VAs ( p = 0.076), compared to patients without CRT‐D; no significant difference in mortality was found between patients with and without CRT‐D ( p = 0.63).
Using X-tile method, we found that patients with a Kyn : Trp ratio less than 0.09 showed a trend for better OS (HR = 0.66, 95% CI, 0.40–1.110; p = 0.076; Figure 3 ).
Men had higher risks of having higher cumulative healthcare visits associated with AS and showed a trend for higher frequency of hospitalization (p = 0.076).
Obese patients demonstrated significantly reduced range of motion in both active forward flexion ( p = 0.035) and external rotation ( p = 0.024), and showed a trend toward higher postoperative pain ( p = 0.076) and poorer functional recovery compared to non-obese patients.
Patients with HALT showed a trend towards smaller AVA at 12 months follow-up (from 1.61 ± 0.42 to 1.51 ± 0.38 cm 2 , p = 0.076), whereas AVA remained unchanged in patients without HALT (from 1.67 ± 0.44 to 1.66 ± 0.44 cm 2 , p = 0.97).